お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書はHIV治療薬市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートはHIV治療薬の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界のHIV治療薬市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートはHIV治療薬のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別にHIV治療薬市場を分類しています。本研究に含まれる主な企業は：Boehringer Ingelheim International GmbH、Merck & Co.、ViiV Healthcare、AbbVie、F. Hoffmann-La Roche Ltd.、Teva Pharmaceutical Industries Ltd.、Bristol-Myers Squibb、Gilead Sciences、Johnson & Johnson、Cipla Limited

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    Entry and Fusion Inhibitors
    Protease Inhibitors (PIs)
    Integrase Inhibitors
    Coreceptor Antagonists

用途別の市場セグメント：
    Hospitals
    Clinics
    Labs

本レポートの詳細内容
世界のHIV治療薬市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、HIV治療薬タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業のHIV治療薬収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のHIV治療薬市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、HIV治療薬市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

HIV治療薬のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：HIV治療薬のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：HIV治療薬の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章HIV治療薬企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：HIV治療薬の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：HIV治療薬の主要企業の概要を提供し、製品の説明と仕様、HIV治療薬の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss of ability to fight against the organism that causes disease.
Market Analysis and Insights: Global HIV Therapeutics Market
The global HIV Therapeutics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for HIV Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of HIV Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for HIV Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the HIV Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global HIV Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for HIV Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Boehringer Ingelheim International GmbH, Merck & Co., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Gilead Sciences and Johnson & Johnson, etc.
Market Segmentation
By Company
    Boehringer Ingelheim International GmbH
    Merck & Co.
    ViiV Healthcare
    AbbVie
    F. Hoffmann-La Roche Ltd.
    Teva Pharmaceutical Industries Ltd.
    Bristol-Myers Squibb
    Gilead Sciences
    Johnson & Johnson
    Cipla Limited

Segment by Type
    Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    Entry and Fusion Inhibitors
    Protease Inhibitors (PIs)
    Integrase Inhibitors
    Coreceptor Antagonists

Segment by Application
    Hospitals
    Clinics
    Labs

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of HIV Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HIV Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HIV Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global HIV Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    Table 3. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    Table 4. Key Players of Entry and Fusion Inhibitors
    Table 5. Key Players of Protease Inhibitors (PIs)
    Table 6. Key Players of Integrase Inhibitors
    Table 7. Key Players of Coreceptor Antagonists
    Table 8. Global HIV Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 9. Global HIV Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 10. Global HIV Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 11. Global HIV Therapeutics Market Share by Region (2019-2024)
    Table 12. Global HIV Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 13. Global HIV Therapeutics Market Share by Region (2025-2030)
    Table 14. HIV Therapeutics Market Trends
    Table 15. HIV Therapeutics Market Drivers
    Table 16. HIV Therapeutics Market Challenges
    Table 17. HIV Therapeutics Market Restraints
    Table 18. Global HIV Therapeutics Revenue by Players (2019-2024) & (US$ Million)
    Table 19. Global HIV Therapeutics Revenue Share by Players (2019-2024)
    Table 20. Global Top HIV Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Therapeutics as of 2023)
    Table 21. Global HIV Therapeutics Industry Ranking 2022 VS 2023 VS 2024
    Table 22. Global 5 Largest Players Market Share by HIV Therapeutics Revenue (CR5 and HHI) & (2019-2024)
    Table 23. Global Key Players of HIV Therapeutics, Headquarters and Area Served
    Table 24. Global Key Players of HIV Therapeutics, Product and Application
    Table 25. Global Key Players of HIV Therapeutics, Product and Application
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global HIV Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 28. Global HIV Therapeutics Revenue Market Share by Type (2019-2024)
    Table 29. Global HIV Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 30. Global HIV Therapeutics Revenue Market Share by Type (2025-2030)
    Table 31. Global HIV Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 32. Global HIV Therapeutics Revenue Share by Application (2019-2024)
    Table 33. Global HIV Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 34. Global HIV Therapeutics Revenue Share by Application (2025-2030)
    Table 35. North America HIV Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 36. North America HIV Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 37. North America HIV Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 38. North America HIV Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 39. North America HIV Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 40. North America HIV Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 41. North America HIV Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 42. Europe HIV Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 43. Europe HIV Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 44. Europe HIV Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 45. Europe HIV Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 46. Europe HIV Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 47. Europe HIV Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 48. Europe HIV Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 49. China HIV Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 50. China HIV Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 51. China HIV Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 52. China HIV Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 53. Asia HIV Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 54. Asia HIV Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 55. Asia HIV Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 56. Asia HIV Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 57. Asia HIV Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 58. Asia HIV Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 59. Asia HIV Therapeutics Market Size by Region (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America HIV Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America HIV Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America HIV Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America HIV Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America HIV Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 65. Middle East, Africa, and Latin America HIV Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 66. Middle East, Africa, and Latin America HIV Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 67. Boehringer Ingelheim International GmbH Company Details
    Table 68. Boehringer Ingelheim International GmbH Business Overview
    Table 69. Boehringer Ingelheim International GmbH HIV Therapeutics Product
    Table 70. Boehringer Ingelheim International GmbH Revenue in HIV Therapeutics Business (2019-2024) & (US$ Million)
    Table 71. Boehringer Ingelheim International GmbH Recent Developments
    Table 72. Merck & Co. Company Details
    Table 73. Merck & Co. Business Overview
    Table 74. Merck & Co. HIV Therapeutics Product
    Table 75. Merck & Co. Revenue in HIV Therapeutics Business (2019-2024) & (US$ Million)
    Table 76. Merck & Co. Recent Developments
    Table 77. ViiV Healthcare Company Details
    Table 78. ViiV Healthcare Business Overview
    Table 79. ViiV Healthcare HIV Therapeutics Product
    Table 80. ViiV Healthcare Revenue in HIV Therapeutics Business (2019-2024) & (US$ Million)
    Table 81. ViiV Healthcare Recent Developments
    Table 82. AbbVie Company Details
    Table 83. AbbVie Business Overview
    Table 84. AbbVie HIV Therapeutics Product
    Table 85. AbbVie Revenue in HIV Therapeutics Business (2019-2024) & (US$ Million)
    Table 86. AbbVie Recent Developments
    Table 87. F. Hoffmann-La Roche Ltd. Company Details
    Table 88. F. Hoffmann-La Roche Ltd. Business Overview
    Table 89. F. Hoffmann-La Roche Ltd. HIV Therapeutics Product
    Table 90. F. Hoffmann-La Roche Ltd. Revenue in HIV Therapeutics Business (2019-2024) & (US$ Million)
    Table 91. F. Hoffmann-La Roche Ltd. Recent Developments
    Table 92. Teva Pharmaceutical Industries Ltd. Company Details
    Table 93. Teva Pharmaceutical Industries Ltd. Business Overview
    Table 94. Teva Pharmaceutical Industries Ltd. HIV Therapeutics Product
    Table 95. Teva Pharmaceutical Industries Ltd. Revenue in HIV Therapeutics Business (2019-2024) & (US$ Million)
    Table 96. Teva Pharmaceutical Industries Ltd. Recent Developments
    Table 97. Bristol-Myers Squibb Company Details
    Table 98. Bristol-Myers Squibb Business Overview
    Table 99. Bristol-Myers Squibb HIV Therapeutics Product
    Table 100. Bristol-Myers Squibb Revenue in HIV Therapeutics Business (2019-2024) & (US$ Million)
    Table 101. Bristol-Myers Squibb Recent Developments
    Table 102. Gilead Sciences Company Details
    Table 103. Gilead Sciences Business Overview
    Table 104. Gilead Sciences HIV Therapeutics Product
    Table 105. Gilead Sciences Revenue in HIV Therapeutics Business (2019-2024) & (US$ Million)
    Table 106. Gilead Sciences Recent Developments
    Table 107. Johnson & Johnson Company Details
    Table 108. Johnson & Johnson Business Overview
    Table 109. Johnson & Johnson HIV Therapeutics Product
    Table 110. Johnson & Johnson Revenue in HIV Therapeutics Business (2019-2024) & (US$ Million)
    Table 111. Johnson & Johnson Recent Developments
    Table 112. Cipla Limited Company Details
    Table 113. Cipla Limited Business Overview
    Table 114. Cipla Limited HIV Therapeutics Product
    Table 115. Cipla Limited Revenue in HIV Therapeutics Business (2019-2024) & (US$ Million)
    Table 116. Cipla Limited Recent Developments
    Table 117. Research Programs/Design for This Report
    Table 118. Key Data Information from Secondary Sources
    Table 119. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global HIV Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global HIV Therapeutics Market Share by Type: 2023 VS 2030
    Figure 3. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Features
    Figure 4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Features
    Figure 5. Entry and Fusion Inhibitors Features
    Figure 6. Protease Inhibitors (PIs) Features
    Figure 7. Integrase Inhibitors Features
    Figure 8. Coreceptor Antagonists Features
    Figure 9. Global HIV Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 10. Global HIV Therapeutics Market Share by Application: 2023 VS 2030
    Figure 11. Hospitals Case Studies
    Figure 12. Clinics Case Studies
    Figure 13. Labs Case Studies
    Figure 14. HIV Therapeutics Report Years Considered
    Figure 15. Global HIV Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 16. Global HIV Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 17. Global HIV Therapeutics Market Share by Region: 2023 VS 2030
    Figure 18. Global HIV Therapeutics Market Share by Players in 2023
    Figure 19. Global Top HIV Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Therapeutics as of 2023)
    Figure 20. The Top 10 and 5 Players Market Share by HIV Therapeutics Revenue in 2023
    Figure 21. North America HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. North America HIV Therapeutics Market Share by Type (2019-2030)
    Figure 23. North America HIV Therapeutics Market Share by Application (2019-2030)
    Figure 24. North America HIV Therapeutics Market Share by Country (2019-2030)
    Figure 25. United States HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Canada HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Europe HIV Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 28. Europe HIV Therapeutics Market Share by Type (2019-2030)
    Figure 29. Europe HIV Therapeutics Market Share by Application (2019-2030)
    Figure 30. Europe HIV Therapeutics Market Share by Country (2019-2030)
    Figure 31. Germany HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. France HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. U.K. HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Italy HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Russia HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Nordic Countries HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. China HIV Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 38. China HIV Therapeutics Market Share by Type (2019-2030)
    Figure 39. China HIV Therapeutics Market Share by Application (2019-2030)
    Figure 40. Asia HIV Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 41. Asia HIV Therapeutics Market Share by Type (2019-2030)
    Figure 42. Asia HIV Therapeutics Market Share by Application (2019-2030)
    Figure 43. Asia HIV Therapeutics Market Share by Region (2019-2030)
    Figure 44. Japan HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. South Korea HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. China Taiwan HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Southeast Asia HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. India HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Australia HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 50. Middle East, Africa, and Latin America HIV Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 51. Middle East, Africa, and Latin America HIV Therapeutics Market Share by Type (2019-2030)
    Figure 52. Middle East, Africa, and Latin America HIV Therapeutics Market Share by Application (2019-2030)
    Figure 53. Middle East, Africa, and Latin America HIV Therapeutics Market Share by Country (2019-2030)
    Figure 54. Brazil HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Mexico HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Turkey HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Saudi Arabia HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. Israel HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. GCC Countries HIV Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 60. Boehringer Ingelheim International GmbH Revenue Growth Rate in HIV Therapeutics Business (2019-2024)
    Figure 61. Merck & Co. Revenue Growth Rate in HIV Therapeutics Business (2019-2024)
    Figure 62. ViiV Healthcare Revenue Growth Rate in HIV Therapeutics Business (2019-2024)
    Figure 63. AbbVie Revenue Growth Rate in HIV Therapeutics Business (2019-2024)
    Figure 64. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in HIV Therapeutics Business (2019-2024)
    Figure 65. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in HIV Therapeutics Business (2019-2024)
    Figure 66. Bristol-Myers Squibb Revenue Growth Rate in HIV Therapeutics Business (2019-2024)
    Figure 67. Gilead Sciences Revenue Growth Rate in HIV Therapeutics Business (2019-2024)
    Figure 68. Johnson & Johnson Revenue Growth Rate in HIV Therapeutics Business (2019-2024)
    Figure 69. Cipla Limited Revenue Growth Rate in HIV Therapeutics Business (2019-2024)
    Figure 70. Bottom-up and Top-down Approaches for This Report
    Figure 71. Data Triangulation
    Figure 72. Key Executives Interviewed